Ivabradinum supplements the clinical efficacy of percutaneous coronary intervention in patients with coronary heart disease with stable angina


Cite item

Full Text

Abstract

The review is devoted to the role of ivabradinum in the procedure of percutaneous coronary intervention (PCI) in patients with ischemic heart disease with stable angina. It is reported that reperfusion of the myocardium with PCI, even in combination with modern drug therapy, does not have a complete clinical effect. The authors substantiate the possibility of completing the clinical effect of PCI in such patients by prescribing ivabradinum. The drug reduces the heart rate more than with medication without it.

About the authors

D. M Aronov

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., рук. лаб. кардиологической реабилитации ФГБУ НМИЦ ПМ, засл. деят. науки РФ 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

M. G Bubnova

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза ФГБУ НМИЦ ПМ 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Boden W.E, O’Rourke R.A, Teo K.K et al. The evolving pattern of symftomatic coronary artery disease in the United and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol 2007.
  2. Boden W.E, O’Rourke R.A, Teo K.K et al. Desing and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperatie Studies Program no.424. Am Heart J 2006; 15 (6): 1173-9.
  3. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial.RITA-2 trial participants. Lancet 1997; 350 (9076): 461-8.
  4. Henderson R.A, Pocock S.J, Clayton T.C et al. Second Randomized Intervention Treatment of Angina (Rita-2) Trial Participants. Seven - year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J AM Coll Cardiol 2003; 42 (7): 1161-70.
  5. Parisi A.F, Folland E.D, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of singl - vessel coronary artery disease. Veterans AffairsA CME Investigators. N Engl J Med 1992; 326 (1): 10-6.
  6. Weintraub W.S, Barnett P, Chen S et al. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline - driven drug Evaluation (COURAGE) trial. Am Heart J 2006; 151 (6): 1180-5.
  7. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949-3003.
  8. Fihn S.D, Gardin J.M, Abrams J et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation. 2012; 126 (25): e354-e471.
  9. Godino C, Colombo A., Margonato A. Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clin Drug Investig 2017; 37 (2): 105-20.
  10. Fox K, Ford I, Steg P.G et al. Ivabradine for patients with stable coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a randomized, double - blind, placebo - controlled trial. Lancet 2008; 372 (9641): 807-16.
  11. Steg P, Lopez-de-Sa E, Schiele F et al. VIVIFY (e Valuation of the Intra Venous If inhibitor ivabradine after ST segment elevation m Yocardial infarction) investigators. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo - controlled, double - blind, pilot study. Eur. Heart J Acute Cardiovasc Care 2013; 2 (3): 270-9.
  12. Werdan K, Ebelt H, Nuding S et al. Ivabradine in combination with beta - blokers in patients with chronic stable angina after percutaneous coronary intervention. Adv Ther 2015; 32 (2): 120-37.
  13. Fox K, Ford I, Steg P.G et al; SIGNIFY Investigators. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J 2015; 36 (46): 3291-6.
  14. Perna G.P, Battistoni I, Angelini L. Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study? G Ital Cardiol (Rome) 2015; 16 (3): 155-60.
  15. Werdan K, Ebelt H, Nuding S et al; on behalf of the ADDITIONS Study Investigators. Ivabradine in combination with Metoprolol improves symftoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trial. Cardiology 2016; 133: 83-90.
  16. Biondi-Zoccai G.G, Abbate A, Agostoni P et al; Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta - analysis of randomized trials. Ital Heart J 2003; 4 (4): 271-80.
  17. Moreyra A.E, Maniatis G.A, Gu H et al; Myocardial Infarction Data Acquisition System (MIDAS 28) Study Group. Frequency of Stroke After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting (from an Eleven - Year Statewide Analysis). Am J Cardiol 2017; 119 (2): 197-202.
  18. Chang M, Lee C.W, Ahn J.M et al. Outcomes of Coronary Artery Bypass Graft Surgery Versus Drug - Eluting Stents in Older Adults. J Am Geriatr Soc 2017; 65 (3): 625-30.
  19. Iqbal M.B, Ilsley C, De Robertis F et al. Comparison of Outcomes of Coronary Artery Bypass Grafting Using Internal Mammary Graft Versus Percutaneous Coronary Intervention for Isolated Proximal Left Anterior Descending Narrowing. Am J Cardiol 2017; 119 (5): 719-26.
  20. Taglimonte E, Cirillo T, Rigo F et al. Ivabradine and Bisoprolol on Doppler - derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther 2015; July 22.
  21. Borer J.S, Heuzey J.Y. Characterization of the heart rate - lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 2008; 15 (5): 461-73.
  22. Ruzyllo W, Tendera M, Ford I et al. Antianginal efficacy and safety of Ivabradine compared with amlodipine in patients in patients with stable effort angina pectoris: a 3-month randomized, double blind, multicentre, noninferiority trial. Drugs 2007; 67 (3): 393-405.
  23. Tardif J.C, Ponikowski P, Kahan T. Efficacy of the I (f) current ingibitior ivabradine patients with chronic stable angina receiving beta - bloker therapyat 4-month, randomized, placebo - controlled trial. Eur Heart J 2009; 30 (5): 540-8.
  24. Skalidis E.I, Hamilos M.I, Chlouverakis G et al. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis 2011; 215 (1): 160-5.
  25. Mangiacapra F, Colaiori, Ricottini E et al. Heart Rate reduction by Ivabradine improvement of endothelial function in patients with coronary artery disease: the RIVENDEL study. Clin Res Cardiol 2017; 106 (1): 69-75.
  26. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by Ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart 2014; 100 (2): 160-6.
  27. Shalnova S.A, Oganov R.G; on behalf of the participants registry clarify. Five Year Dynamics of Main Clinical Symftoms in Patients Wits Ischemic Heart Disease in Russia in Comparison With Other Countries (the CLARIFY Registry). Kardiologiia. 2017.

Copyright (c) 2017 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies